| Scott Dennis Poynter, CRNA | |
|
1514 Jefferson Hwy, New Orleans, LA 70121-2429 | |
| (504) 842-3755 | |
| Not Available |
| Full Name | Scott Dennis Poynter |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 18 Years |
| Location | 1514 Jefferson Hwy, New Orleans, Louisiana |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1043418981 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ochsner Clinic Foundation | New orleans, LA | Hospital |
| Touro Infirmary | New orleans, LA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesiology Group Associates Inc | 0042110298 | 151 |
| Childrens Hospital Anesthesia Corporation | 0446152862 | 221 |
| Ochsner Clinic Llc | 8224933619 | 2403 |
News Archive
Millions of people today take statins to help lower their cholesterol level. Currently statins are prescribed to patients based on their future risk of cardiovascular disease - mainly driven by age - which excludes many individuals who may benefit from them. A new study led by the Research Institute of the McGill University Health Centre in Montreal, with collaborators from the United-States, is changing the way we think about prescribing statins. The research team has developed a new approach to determine which individuals should receive these important medications.
The Pacific island nations are falling back on immunization targets, especially those for diseases spread through mother-to-child transmission, according to WHO officials.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the commencement of a Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease. The company also announced that GMI-1070 has received Fast Track designation from the U.S. Food and Drug Administration.
WILD Flavors, Inc. is excited to announce a recently formed partnership with Sterling Technology. This new partnership makes WILD the exclusive provider of both Immunel and Tegricel.
Telstra Health today launched ReadyCare, its GP telemedicine service that gives Australians the choice to connect with a doctor using phone or video and receive advice, treatment, diagnosis and prescriptions.
› Verified 3 days ago
| Entity Name | Ochsner Clinic Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538151428 PECOS PAC ID: 8224933619 Enrollment ID: O20031126000513 |
News Archive
Millions of people today take statins to help lower their cholesterol level. Currently statins are prescribed to patients based on their future risk of cardiovascular disease - mainly driven by age - which excludes many individuals who may benefit from them. A new study led by the Research Institute of the McGill University Health Centre in Montreal, with collaborators from the United-States, is changing the way we think about prescribing statins. The research team has developed a new approach to determine which individuals should receive these important medications.
The Pacific island nations are falling back on immunization targets, especially those for diseases spread through mother-to-child transmission, according to WHO officials.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the commencement of a Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease. The company also announced that GMI-1070 has received Fast Track designation from the U.S. Food and Drug Administration.
WILD Flavors, Inc. is excited to announce a recently formed partnership with Sterling Technology. This new partnership makes WILD the exclusive provider of both Immunel and Tegricel.
Telstra Health today launched ReadyCare, its GP telemedicine service that gives Australians the choice to connect with a doctor using phone or video and receive advice, treatment, diagnosis and prescriptions.
› Verified 3 days ago
| Entity Name | Anesthesiology Group Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255399598 PECOS PAC ID: 0042110298 Enrollment ID: O20040113000117 |
News Archive
Millions of people today take statins to help lower their cholesterol level. Currently statins are prescribed to patients based on their future risk of cardiovascular disease - mainly driven by age - which excludes many individuals who may benefit from them. A new study led by the Research Institute of the McGill University Health Centre in Montreal, with collaborators from the United-States, is changing the way we think about prescribing statins. The research team has developed a new approach to determine which individuals should receive these important medications.
The Pacific island nations are falling back on immunization targets, especially those for diseases spread through mother-to-child transmission, according to WHO officials.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the commencement of a Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease. The company also announced that GMI-1070 has received Fast Track designation from the U.S. Food and Drug Administration.
WILD Flavors, Inc. is excited to announce a recently formed partnership with Sterling Technology. This new partnership makes WILD the exclusive provider of both Immunel and Tegricel.
Telstra Health today launched ReadyCare, its GP telemedicine service that gives Australians the choice to connect with a doctor using phone or video and receive advice, treatment, diagnosis and prescriptions.
› Verified 3 days ago
| Entity Name | Childrens Hospital Anesthesia Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649362740 PECOS PAC ID: 0446152862 Enrollment ID: O20040124000258 |
News Archive
Millions of people today take statins to help lower their cholesterol level. Currently statins are prescribed to patients based on their future risk of cardiovascular disease - mainly driven by age - which excludes many individuals who may benefit from them. A new study led by the Research Institute of the McGill University Health Centre in Montreal, with collaborators from the United-States, is changing the way we think about prescribing statins. The research team has developed a new approach to determine which individuals should receive these important medications.
The Pacific island nations are falling back on immunization targets, especially those for diseases spread through mother-to-child transmission, according to WHO officials.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the commencement of a Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease. The company also announced that GMI-1070 has received Fast Track designation from the U.S. Food and Drug Administration.
WILD Flavors, Inc. is excited to announce a recently formed partnership with Sterling Technology. This new partnership makes WILD the exclusive provider of both Immunel and Tegricel.
Telstra Health today launched ReadyCare, its GP telemedicine service that gives Australians the choice to connect with a doctor using phone or video and receive advice, treatment, diagnosis and prescriptions.
› Verified 3 days ago
| Entity Name | Youngs Professional Services Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1922178599 PECOS PAC ID: 2163524992 Enrollment ID: O20070226000608 |
News Archive
Millions of people today take statins to help lower their cholesterol level. Currently statins are prescribed to patients based on their future risk of cardiovascular disease - mainly driven by age - which excludes many individuals who may benefit from them. A new study led by the Research Institute of the McGill University Health Centre in Montreal, with collaborators from the United-States, is changing the way we think about prescribing statins. The research team has developed a new approach to determine which individuals should receive these important medications.
The Pacific island nations are falling back on immunization targets, especially those for diseases spread through mother-to-child transmission, according to WHO officials.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the commencement of a Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease. The company also announced that GMI-1070 has received Fast Track designation from the U.S. Food and Drug Administration.
WILD Flavors, Inc. is excited to announce a recently formed partnership with Sterling Technology. This new partnership makes WILD the exclusive provider of both Immunel and Tegricel.
Telstra Health today launched ReadyCare, its GP telemedicine service that gives Australians the choice to connect with a doctor using phone or video and receive advice, treatment, diagnosis and prescriptions.
› Verified 3 days ago
| Entity Name | Parish Anesthesia Of Tulane |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1588998231 PECOS PAC ID: 5496897753 Enrollment ID: O20100125000469 |
News Archive
Millions of people today take statins to help lower their cholesterol level. Currently statins are prescribed to patients based on their future risk of cardiovascular disease - mainly driven by age - which excludes many individuals who may benefit from them. A new study led by the Research Institute of the McGill University Health Centre in Montreal, with collaborators from the United-States, is changing the way we think about prescribing statins. The research team has developed a new approach to determine which individuals should receive these important medications.
The Pacific island nations are falling back on immunization targets, especially those for diseases spread through mother-to-child transmission, according to WHO officials.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the commencement of a Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease. The company also announced that GMI-1070 has received Fast Track designation from the U.S. Food and Drug Administration.
WILD Flavors, Inc. is excited to announce a recently formed partnership with Sterling Technology. This new partnership makes WILD the exclusive provider of both Immunel and Tegricel.
Telstra Health today launched ReadyCare, its GP telemedicine service that gives Australians the choice to connect with a doctor using phone or video and receive advice, treatment, diagnosis and prescriptions.
› Verified 3 days ago
| Entity Name | Zephyr Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891087458 PECOS PAC ID: 1658559125 Enrollment ID: O20110705000180 |
News Archive
Millions of people today take statins to help lower their cholesterol level. Currently statins are prescribed to patients based on their future risk of cardiovascular disease - mainly driven by age - which excludes many individuals who may benefit from them. A new study led by the Research Institute of the McGill University Health Centre in Montreal, with collaborators from the United-States, is changing the way we think about prescribing statins. The research team has developed a new approach to determine which individuals should receive these important medications.
The Pacific island nations are falling back on immunization targets, especially those for diseases spread through mother-to-child transmission, according to WHO officials.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the commencement of a Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease. The company also announced that GMI-1070 has received Fast Track designation from the U.S. Food and Drug Administration.
WILD Flavors, Inc. is excited to announce a recently formed partnership with Sterling Technology. This new partnership makes WILD the exclusive provider of both Immunel and Tegricel.
Telstra Health today launched ReadyCare, its GP telemedicine service that gives Australians the choice to connect with a doctor using phone or video and receive advice, treatment, diagnosis and prescriptions.
› Verified 3 days ago
| Entity Name | Symvios Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427746619 PECOS PAC ID: 8729446521 Enrollment ID: O20230627002071 |
News Archive
Millions of people today take statins to help lower their cholesterol level. Currently statins are prescribed to patients based on their future risk of cardiovascular disease - mainly driven by age - which excludes many individuals who may benefit from them. A new study led by the Research Institute of the McGill University Health Centre in Montreal, with collaborators from the United-States, is changing the way we think about prescribing statins. The research team has developed a new approach to determine which individuals should receive these important medications.
The Pacific island nations are falling back on immunization targets, especially those for diseases spread through mother-to-child transmission, according to WHO officials.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the commencement of a Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease. The company also announced that GMI-1070 has received Fast Track designation from the U.S. Food and Drug Administration.
WILD Flavors, Inc. is excited to announce a recently formed partnership with Sterling Technology. This new partnership makes WILD the exclusive provider of both Immunel and Tegricel.
Telstra Health today launched ReadyCare, its GP telemedicine service that gives Australians the choice to connect with a doctor using phone or video and receive advice, treatment, diagnosis and prescriptions.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott Dennis Poynter, CRNA 1514 Jefferson Hwy, New Orleans, LA 70121-2429 Ph: (504) 842-4000 | Scott Dennis Poynter, CRNA 1514 Jefferson Hwy, New Orleans, LA 70121-2429 Ph: (504) 842-3755 |
News Archive
Millions of people today take statins to help lower their cholesterol level. Currently statins are prescribed to patients based on their future risk of cardiovascular disease - mainly driven by age - which excludes many individuals who may benefit from them. A new study led by the Research Institute of the McGill University Health Centre in Montreal, with collaborators from the United-States, is changing the way we think about prescribing statins. The research team has developed a new approach to determine which individuals should receive these important medications.
The Pacific island nations are falling back on immunization targets, especially those for diseases spread through mother-to-child transmission, according to WHO officials.
GlycoMimetics, Inc., a clinical-stage biotechnology company developing a new class of glycobiology-based therapies for a broad range of indications, today announced the commencement of a Phase 2 clinical trial of GMI-1070 for treatment of vaso-occlusive crisis of sickle cell disease. The company also announced that GMI-1070 has received Fast Track designation from the U.S. Food and Drug Administration.
WILD Flavors, Inc. is excited to announce a recently formed partnership with Sterling Technology. This new partnership makes WILD the exclusive provider of both Immunel and Tegricel.
Telstra Health today launched ReadyCare, its GP telemedicine service that gives Australians the choice to connect with a doctor using phone or video and receive advice, treatment, diagnosis and prescriptions.
› Verified 3 days ago
Wendy Lynn Cambre, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1514 Jefferson Hwy, New Orleans, LA 70121 Phone: 504-842-3755 | |
Lyndsey Launa Martin, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1514 Jefferson Hwy, New Orleans, LA 70121 Phone: 504-842-3755 | |
Harold Stevenon Mustin Iii, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2021 Perdido St, New Orleans, LA 70112 Phone: 504-903-3370 Fax: 504-897-7008 | |
Lisa Battley, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1514 Jefferson Hwy, New Orleans, LA 70121 Phone: 504-842-4000 | |
Paige Crespo, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1514 Jefferson Hwy, New Orleans, LA 70121 Phone: 504-842-4000 | |
Stephen Michael Kelly, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 2021 Perdido St, New Orleans, LA 70112 Phone: 504-903-3370 | |
Ashlee Babst, Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 2021 Perdido St, New Orleans, LA 70112 Phone: 504-875-9750 |